Loading company…
Samabriva uses plant-based bioproduction technology to produce molecules for pharmaceutical and API markets.
Founded in 2011, Samabriva uses automated plant-based bioproduction to produce molecules, including natural active compounds, recombinant proteins, and VLPs. Its processes serve biopharmaceutical and API markets. The company is based in Amiens, France, and is led by CEO Marina Guillet. In December 2023, it raised EUR 4 million in Series A funding co-led by Noshaq and Investsud to develop a production site in Liège, Belgium.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in